BioSpace News Archive

Cedilla Therapeutics today announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance.

INOVIO (NASDAQ: INO), today announced that several volunteers have been dosed with its DNA-based, intradermal Ebola vaccine candidate, INO-4201, as part of a randomized, placebo-controlled, Phase 1b clinical trial (NCT04906629).

Rebus Biosystems Inc. today announced that Viet Truong and Ramesh Ramakrishnan, Ph.D., have joined the Company’s management team

Polypeptide Therapeutic Solutions today announced the appointment of Robert Shaw as Chief Executive Officer.

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, launched a multi-part corporate video series entitled “Remaking Medicine: On The Record.” The series is moderated by Jami Rubin, EQRx’s chief financial officer, and features EQRx senior leadership team members, board directors, investors and external advisors.

Rakovina Therapeutics Inc. announced that the Company has been selected to join a three year US$975,000 research program funded by the St. Baldrick’s Foundation Martha’s BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults.

illumigyn, the world’s first remote gynecological imaging platform, announced today its new distribution agreement with Lambell Ghana Limited to deploy 850 Gynescopes in Ghana by 2026, to expand access to vital care for women worldwide.

PacBio (Nasdaq: PACB), today announced the launch of the HiFiViral SARS-CoV-2 Kit – a fully kitted end-to-end solution for COVID-19 surveillance, which public health laboratories can use to identify new SARS-CoV-2 variants and detect all variants circulating within a population.

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnostics and oncological research, announced today that it has partnered with Arizona State University to develop a COVID-19 “Correlate of Protection” using AXIM’s rapid neutralizing antibody test.